Olverembatinib for FGFR1-rearranged Neoplasms

Status Recruiting

Clinical Trial Summary

FGFR1-rearranged myeloid/lymphoid neoplasms are a rare hematologic malignancy with very poor outcome despite intensive chemotherapy. The only curative option is thought to be allogeneic hematopoietic stem cell transplantation (HSCT) in remission. This phase II study is aimed to evaluate the efficacy of Olverembatinib, consolidated with HSCT in the treatment of FGFR1-rearranged myeloid/lymphoid neoplasm.

Clinical Trial Description

FGFR1-rearranged myeloid/lymphoid neoplasms are a rare and highly heterogeneous hematological malignancy, mainly manifested as myeloproliferative neoplasms (MPNs) or acute leukemia, including T cells or B cells Cell lymphoblastic leukemia/lymphoma (T-cell or B-cell-ALL/LBL), acute myeloid leukemia (AML) and mixed cell leukemia (MPAL). To date, there is no standard treatment. Conventional chemotherapy is frequently ineffective. The only curative option is thought to be allogeneic HSCT at present, TKIs may offer a therapeutic alternative in patients not eligible for allogeneic HSCT or to bridge the time between diagnosis and allogeneic HSCT. Third-generation TKIs Olverembatinib is a pan- FGFR1 kinase inhibitor, and is supposed to be effective to achieve bone marrow remission in FGFR1-rearranged myeloid/lymphoid neoplasms. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05521204
Study type	Interventional
Source	The First Affiliated Hospital of Soochow University
Contact	Suning Chen
Phone	+86-13814881746
Email	chensuning@sina.com
Status	Recruiting
Phase	Phase 2
Start date	September 1, 2022
Completion date	August 31, 2027

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05088356` - Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft	Phase 1
Recruiting	`NCT04904588` - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide	Phase 2
Recruiting	`NCT04969601` - Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings	Phase 1/Phase 2
Recruiting	`NCT02356159` - Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation	Phase 1/Phase 2
Withdrawn	`NCT05170828` - Cryopreserved MMUD BM With PTCy for Hematologic Malignancies	Phase 1
Terminated	`NCT02877082` - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients	Phase 2
Active, not recruiting	`NCT01956630` - Clinical Study of DC Plus CIK for Patients With Relapse Acute Leukemia After Allo-HSCT	Phase 1/Phase 2
Completed	`NCT00988013` - Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies	N/A
Enrolling by invitation	`NCT01728402` - Pathogenesis of Hematologic Malignancies
Active, not recruiting	`NCT03595800` - Extension of a Study of Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor to Younger Patients Eligible for Reduced-intensity Conditioning Regimen	Phase 3
Completed	`NCT02440178` - Micafungin Prophylaxis During 1st Induction Chemotherapy for De Novo Acute Leukemia	Phase 2
Recruiting	`NCT05071482` - Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL	Phase 4
Withdrawn	`NCT03138395` - iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML	N/A
Completed	`NCT03042676` - Electronic Database for the Follow up of the ATG_FamilyStudy
Completed	`NCT04597086` - Bright White Light Therapy for the Improvement of Sleep, Fatigue, Distress, Depression, and Anxiety in Hospitalized Leukemia Patients	N/A
Terminated	`NCT03588936` - Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant	Phase 1
Not yet recruiting	`NCT04084327` - Immunophenotyping of Acute b Cell Lymphoblstic Leukemia
Terminated	`NCT00852709` - Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias	Phase 1
Not yet recruiting	`NCT06026839` - Longitudinal Study on the QoL of Pediatric Patients After HSCT and Its Influencing Factors
Completed	`NCT00520130` - Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System	Phase 1/Phase 2